116 results about "Infection induced" patented technology

The present invention belongs to the field of virus detection technology, and specifically relates to monoclonal antibodies with neutralizing activity against adenovirus type 5 and their uses. The monoclonal antibody 8B9 of the present invention can specifically recognize and neutralize adenovirus type 5, and the amino acid sequences of the heavy and light chain variable regions and their complementarity determining regions of the monoclonal antibody 8B9 are provided. The present invention also provides an in vitro neutralization activity assessment model based on HEK-293A cells. At a concentration as low as 3.3 μg / mL, the titer of the neutralizing activity against the virus stock solution after 6000-fold dilution is 7×10 4 TCID 50 / mL of virus has close to 100% neutralizing activity. After further humanization, it is expected to be developed into a neutralizing antibody drug for the treatment of diseases such as severe pneumonia caused by HADV-5 infection, filling the current lack of effective treatment options in this field and possessing significant scientific research value and clinical application prospects.

The invention discloses glucoside hydrolase with anti-biofilm activity and application of the glucoside hydrolase. Experiments prove that the PgaBAb1 protein and the PgaBKp protein have remarkable anti-staphylococcus epidermidis biofilm activity and can destroy a mature staphylococcus epidermidis biofilm and inhibit formation of the staphylococcus epidermidis biofilm, that is, the PgaBAb1 protein and the PgaBKp protein are glucoside hydrolase with anti-biofilm activity; meanwhile, the sensitivity of the staphylococcus epidermidis to methicillin can be improved; the amino acid sequences of the PgaBAb1 protein and the PgaBKp protein are respectively as shown in SEQ ID NO: 5 and SEQ ID NO: 6. Therefore, both the PgaBAb1 protein and the PgaBKp protein can be used as active ingredients of drugs to treat diseases caused by infection of bacteria generating biological membranes and / or drug-resistant bacteria. The method has an important application value.

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

The invention belongs to the technical field of biology, and discloses application of wogonin in resisting siniperca chuatsi and frog iridovirus, the wogonin can effectively inhibit over-generation of ROS caused by MRV virus infection, and oxidative stress damage of host cells is relieved in a dose-dependent mode. The wogonin can be used for preventing and treating the siniperca chuatsi and frog iridovirus, the high expression state of a proinflammatory gene can be reduced, intestinal tissue damage induced by MRV infection can be relieved, proliferation of MRV in the micropterus salmoides is effectively inhibited, the MRV challenge survival rate of the micropterus salmoides is increased, a basis is provided for preparing a product for resisting the siniperca chuatsi and frog iridovirus from wogonin, and the wogonin has important application value. Meanwhile, the invention also discloses a medicine, a fish feed and a fish feed additive of the wogonin.

The present invention relates to a composition for treatment of coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, an early full recovery effect has been confirmed through the efficacy of treating clinical symptoms caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, alleviating inflammation, and inhibiting inflammatory cytokines using a pharmaceutically acceptable salt of taurodeoxycholic acid, and thus the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a composition for prevention or treatment of lower respiratory tract infectious diseases, including coronavirus disease 2019.

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.

The invention provides application of sclareol in preparation of a medicine for preventing and treating varicella-zoster virus infection. A series of biological experiments show that the sclareol can obviously relieve the cytopathic effect caused by VZV infection under the concentration without obvious cytotoxicity; the gene expression quantity of VZV characteristic genes including an immediate early gene ORF62, an early gene ORF21 and a late gene ORF68 and the expression of an early protein IE62 and a late protein gE can be remarkably inhibited, so that the effect of resisting VZV infection is achieved. The results show that sclareol has obvious prevention and treatment effects on VZV, has small toxic and side effects, is safe and effective, and has an application prospect in preparation of drugs for treating and / or preventing VZV.

The invention belongs to the technical field of biological medicines, and particularly relates to application of UH15-38 in preparation of a medicine for preventing and treating PEDV-PoRVA co-infection. According to the invention, a PEDV and PoRVA co-infected piglet model is systematically established for the first time, a high-throughput transcriptomics means is combined, an enhancement mechanism of co-infection on host pathogenicity is deeply analyzed from an immune regulation level, and based on the mechanism, UH15-38 is found to be capable of effectively treating PEDV and PoRVA co-infected piglets. Experimental data show that the UH15-38 remarkably relieves clinical diarrhea symptoms caused by co-infection, reduces the copy number of PoRVA and PEDV viruses, effectively inhibits duplication of the viruses in intestinal tracts, remarkably reduces the expression levels of IL-1beta and p-MLKL in jejunum tissues, and reduces necrotic apoptosis and inflammatory response. The UH15-38 can provide a new application value for the treatment of the porcine viral diarrhea.

The invention belongs to the technical field of application of natural products, and particularly relates to an anti-helicobacter pylori natural product composition and application, the anti-helicobacter pylori natural product composition comprises raspberry extract and cinnamon extract, and the composition contains anti-helicobacter pylori active substances. Besides, the natural product composition is combined with a clinical standard treatment method for treating helicobacter pylori, so that the curative effect can be further improved, and the gastrointestinal motility can be enhanced by adjusting intestinal flora disorder caused by pylorus infection, reducing toxic and side effects of antibiotic treatment, protecting gastric mucosa and enhancing gastrointestinal motility. The composition consists of two natural medicinal and edible plant extracts, is suitable for long-term use and has few adverse reactions. The Lycojaponicumin C can be used for preparing anti-helicobacter pylori medicines and preventive health-care foods, has obvious significance in prevention and treatment of helicobacter pylori infection, and has a good development prospect.

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.

It discloses a method for the treatment of disease caused by HIV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound (1) or a pharmaceutically acceptable salt thereof.

The invention discloses a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection. The invention relates to a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection, and discloses that tripterine can effectively inhibit inflammatory response caused by severe influenza A virus infection and reduce pathological injury of lungs without affecting antiviral immune response.

The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.

The invention belongs to the technical field of biological medicine, and particularly relates to a monoclonal antibody for resisting novel coronavirus and application of the monoclonal antibody. In particular, the present invention relates to monoclonal antibodies against novel coronaviruses, as well as compositions (e.g., diagnostic and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosing, preventing and / or treating infection of novel coronavirus and / or diseases caused by the infection.

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.

The invention discloses application of difluoromethyl ornithine in preparation of a medicine for preventing and / or treating diseases caused by porcine circovirus type 2 infection, and belongs to the technical field of biology. It is found that difluoromethyl ornithine can efficiently inhibit infection of the porcine circovirus type 2 to host cells and mice, reduce the virus titer of the porcine circovirus type 2, inhibit expression of Cap protein of the porcine circovirus type 2, significantly reduce the virus load in mice and relieve infection symptoms. And the difluoromethyl ornithine is relatively low in cytotoxicity and has no obvious toxic and side effects on mice. The difluoromethyl ornithine can be used for preparing the medicine for resisting the porcine circovirus type 2, and a new treatment choice is provided for preventing and treating porcine circovirus type 2 infection and porcine circovirus related diseases in actual pig raising production.

The invention belongs to the technical field of bioengineering, and particularly provides application of a JNK inhibitor in preparation of drugs for preventing and / or relieving and / or treating pulmonary tuberculosis aiming at the problem that whether the existing JNK inhibitor SP600125 can inhibit BNIP3-mediated mitochondrial autophagy and further exert the ROS bactericidal effect is unknown. And the JNK inhibitor is an SP600125 JNK inhibitor. The JNK inhibitor is used for inhibiting mitochondrial autophagy in the BCG infected macrophages. The JNK inhibitor reduces the up-regulation of BNIP3 and LC3B caused by BCG infection. It is found through the application that when the concentration of the JNK inhibitor reaches 15 umol / L, remarkable cytotoxicity begins to appear, and compared with a control group, the cell survival rate is remarkably decreased. The SP600125 can be used for inhibiting mitochondrial autophagy and down-regulating the expression of BNIP3 and LC3B. Inhibition of JNK expression can inhibit survival of Mtb in RAW264.7 macrophages, and a new thought and direction are provided for treatment of tuberculosis.

The invention relates to the technical field of materials for preventing and treating local infection, in particular to drug-loaded composite nanoparticles as well as a preparation method and application thereof. The drug-loaded composite nanoparticles provided by the invention comprise hollow polydopamine grafted with vancomycin and lipoic acid-quaternary ammonium salt ionic liquid loaded into a cavity of the hollow polydopamine. In the invention, the HPDA nanoparticles have a hollow structure, and the structure provides sufficient space for loading of drug molecules. The lipoic acid-quaternary ammonium salt ionic liquid can generate heat energy under the microwave heat effect, and bacteria are effectively killed. Besides, under microwave stimulation, the lipoic acid-quaternary ammonium salt ionic liquid not only can enhance the sterilization effect, but also can reduce inflammatory response caused by bacterial infection through the synergistic effect of microwave heat effect and chemical sterilization.

The invention relates to a fusion protein for preventing klebsiella pneumoniae infection, an immunogenic composition, a recombinant vaccine, a molecular architecture design, application and the like. The invention provides a vaccine for independently expressing a PstS antigen and a vaccine for expressing a fusion protein of YidR-PstS or PstS-YidR, and elements such as an Fc structural domain and STABILON are added. The invention also provides corresponding recombinant nucleic acid, a gene expression cassette, a vector, a host cell, a pharmaceutical composition, a vaccine, application and the like. The vaccine can weaken tissue lesions caused by klebsiella pneumoniae infection, has good immunogenicity, plays effective prevention and immune protection roles, efficiently prevents klebsiella pneumoniae infection, and has wide application prospects.

The present invention belongs to the technical field of aspergillosis treatment, and specifically discloses the use of carbonyl cyanide-4-trifluoromethoxyphenylhydrazone in the prevention and treatment of Aspergillus fumigatus infection, that is, using it as the sole active ingredient in the preparation of a drug for preventing or treating diseases caused by Aspergillus fumigatus infection, or for the preparation of an antibacterial and / or bactericidal product for Aspergillus fumigatus. The present invention first discovered that carbonyl cyanide-4-trifluoromethoxyphenylhydrazone has a significant inhibitory effect on both wild-type and drug-resistant strains of the human pathogenic fungus Aspergillus fumigatus, and can inhibit its colony growth, hyphal growth, and conidia formation, thereby providing a new therapeutic drug for Aspergillus fumigatus infection. At the same time, it solves the problem of antibiotic resistance that plagues the clinical treatment of Aspergillus fumigatus infection, and can circumvent the disadvantage that antibiotics are prone to drug resistance.

The invention relates to the fields of immunology and molecular virology, in particular to the fields of prevention and treatment of RSV (Respiratory Syndrome Virus). Specifically, the invention provides a monoclonal antibody capable of specifically binding to a neoepitope on pre-F protein, and application of the monoclonal antibody to detection, prevention and / or treatment of RSV infection and / or diseases caused by the infection.

The invention provides an application of OICR-9429 or a pharmaceutically acceptable salt thereof in preparation of a product for improving senescence indications. The OICR-9429 provided by the invention shows multiple beneficial technical effects in the aspect of improving senescence-related indications, not only can effectively relieve inflammatory response caused by pyroptosis in the senescence process, but also can improve the immune function and anti-infection ability of senescence organisms. The OICR-9429 also has a remarkable treatment effect on sepsis, the increase of the inflammation level caused by infection is inhibited, the survival rate of old patients is increased, and the prognosis is improved. Long-term intervention of the OICR-9429 can continuously relieve the chronic inflammation state of an aging body, increase the muscle mass, enhance the exercise ability, prolong the life and reduce various lesions accompanied by aging. The invention lays a foundation for developing products for comprehensively intervening aging and related function decline, and has important application value in the aspect of improving the life quality of old people.

The present invention refers to the veterinary field. Particularly, it refers to a strain of Glaesserella parasuis, or a composition comprising thereof. Preferably, the strain or composition is for use in a method for the prevention and / or treatment of Glässer's disease or a condition caused by infection with a virulent Glaesserella parasuis strain. It also refers to a device suitable for administering a medicine to porcine animals characterized in that it comprises a non-virulent live strain of Glaesserella parasuis.

The invention provides application of 7, 8-dihydroxyflavone in preparation of a medicine for treating diseases caused by herpes virus infection, and belongs to the technical field of biological medicine. The 7, 8-dihydroxy flavone can be used for remarkably inhibiting infection of herpes simplex viruses HSV-1 and HSV-2, and has broad-spectrum anti-HSV activity. According to the present invention, the HSV virus protein expression can be significantly inhibited by pretreating the virus with the 1, 7, 8-dihydroxyflavone and treating the cells after the virus adsorption, the virus plaque formation can be reduced, and the dose dependence can be provided; experiments show that the 7, 8-dihydroxyflavone plays the anti-herpes simplex virus activity mainly through targeting host protein fructose-diphosphate aldolase A. The 7, 8-dihydroxyflavone has the anti-herpes simplex virus activity. Mouse in-vivo experiments prove that the 7, 8-dihydroxyflavone can significantly improve the survival rate of HSV-1 mice, improve the weight reduction trend and reduce the virus titer of lung tissues; meanwhile, mouse genital organ lesions caused by HSV-2 infection can be remarkably relieved, and the weight of infected mice is improved. Therefore, the compound 7, 8-dihydroxyflavone is expected to be developed into a candidate drug for treating the herpes simplex virus.

The application discloses an oil and fat composition for resisting porcine enterovirus infection and application thereof. The oil and fat composition comprises at least two of glyceryl monopentanoate, glyceryl monolinoleate and glyceryl monomyristate. The oil and fat composition can further comprise anhydrous ethanol, propylene glycol, dimethyl sulfoxide, edible oil, Tween 80, lactose, mannitol, soluble starch, water and other auxiliary materials for preparing oil and fat composition preparations. The oil and fat composition can inhibit enterovirus through multiple channels and multiple levels, and improve the antiviral effect. Adding the oil and fat composition in the feed of pigs can not only improve the antiviral ability, but also reduce the inflammatory reaction caused by pathogenic infection through the anti-inflammatory and immune regulation effects, effectively prevent and treat the infection of porcine enterovirus diarrhea, and thus reduce the incidence of porcine enterovirus diarrhea and the mortality of pigs with the disease. The oil and fat composition can be used for preparing a medicine or a feed additive for treating and preventing porcine enterovirus diarrhea.

The application provides a combined medicine containing a nitrothiazolyl acid amide derivative and application thereof, and belongs to the field of chemical medicines. The combined medicine contains component A and component B which are administered simultaneously or separately and have the same or different specifications, and a pharmaceutically acceptable carrier. The component A is a nitrothiazolyl acid amide derivative shown in formula I, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The component B is a fatty acid, or a pharmaceutically acceptable salt thereof, or a crystal form thereof. The combined medicine is used for preventing and / or treating infections and related diseases. The combined medicine can produce a synergistic effect, is used for treating viral, bacterial and parasitic infections and related diseases, and has a good treatment effect. Meanwhile, the combined medicine has good safety in use, provides a new choice for clinically treating infections and related diseases caused by infections, and has a good application prospect.